David Gómez-Almaguer
David Gómez-Almaguer is an expert in Hematology at Hospital Universitario Dr José Eleuterio Gonzalez (Mexico). As of October 2026, ScienceLeadR ranks David Gómez-Almaguer in the top 1% of experts worldwide for Stem Cell Transplantation, Cell Transplantation and Cytopenia. David Gómez-Almaguer has authored 575 publications, the most recent in 2026, and is an investigator in 34 clinical trials, 9 of them ongoing. SLR score: 2,468 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Transplantation - Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1981 - 2026
Number : 575
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Teclistamab desensitization of donor-specific antibodies in aplastic anemia. PMID 42817847 — anemia, aplastic, hematology, antibodies, anemia | Haematologica | 2026 | 0 |
| Impact of graft-versus-host disease on relapse and survival in adults with B-cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation plus post-transplant cyclophosphamide in resource-limited settings. PMID 42686101 — cells, mortality, precursor cell lymphoblastic leukemia-lymphoma, microscopy, electron, scanning transmission, incidence, hematopoietic stem cell transplantation, cyclophosphamide, leukemia, stem cells, graft vs host disease, transplants, cell transplantation, stem cell transplantation, hematopoietic stem cells, b-lymphocytes, transplantation | Transplant Cell Ther | 2026 | 0 |
| Response to Correspondence Regarding "Simplification of Hematopoietic Stem Cell Transplantation and Continued FACT Accreditation: Strategies for Low- and Middle-Income Countries". PMID 42567276 — cells, microscopy, electron, scanning transmission, hematopoietic stem cell transplantation, income, stem cells, cell transplantation, stem cell transplantation, hematopoietic stem cells, transplantation | Transplant Cell Ther | 2026 | 0 |
| Improving engraftment in autologous hematopoietic stem cell transplantation: comparing pegfilgrastim with filgrastim in an outpatient setting. PMID 42531780 — cells, febrile neutropenia, microscopy, electron, scanning transmission, incidence, hematopoietic stem cell transplantation, neutropenia, stem cells, filgrastim, cell transplantation, stem cell transplantation, blood platelets, outpatients, hematopoietic stem cells, transplantation, biosimilar pharmaceuticals | Hematol Transfus Cell Ther | 2026 | 0 |
| Mapping the capacity for geriatric blood Cancer Care in Latin America: A cross- sectional survey of current status and future priorities. PMID 42485998 — cross-sectional studies, blood, geriatricians, hematologic neoplasms, neoplasms, geriatric assessment, transplants, research, workforce | J Geriatr Oncol | 2026 | 0 |
Clinical Studies 34
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
9 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib NCT07623161 — injections, safety, anemia, pharmaceutical preparations, drug therapy, therapeutics, primary myelofibrosis | Phase 3 | Recruiting | 2026 |
| A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions NCT07422480 — injections, cells, blood transfusion, epoetin alfa, myelodysplastic syndromes, safety, erythrocytes, blood, erythrocyte transfusion, anemia, pharmaceutical preparations, drug therapy, blood cells, therapeutics | Phase 3 | Recruiting | 2026 |
| Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment NCT06904599 — chorionic gonadotropin, cells, prednisone, dexamethasone, gonadotropins, graft vs host disease, transplants, therapeutics, cell transplantation, transplantation | Phase 2 | Recruiting | 2025 |
| Efficacy of Short course Blinatumomab for MRD Erradication in B ALL NCT06886074 — burkitt lymphoma, cells, precursor cell lymphoblastic leukemia-lymphoma, incidence, dexamethasone, lymphoma, neoplasms, leukemia, neoplasm, residual, transplants, therapeutics, chromosomes, philadelphia chromosome, b-lymphocytes | Phase 2 | Recruiting | 2025 |
| Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients NCT06758375 — neoplasms, plasma cell, cells, plasma cells, neoplasms, multiple myeloma, therapeutics, plasma | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map